TP05

DRUG2 trials

Sponsors

Tillotts Pharma AG

Conditions

Acute Ulcerative ColitisUlcerative Colitis

Phase 1

TP0502-B-Pharmaco-Scintigraphic-Study

CompletedNCT02306798

Tillotts Pharma AGUlcerative Colitis

Start: 2013-09-30End: 2013-12-31Updated: 2014-12-04

Phase 3

TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)

CompletedNCT01903252

Tillotts Pharma AGAcute Ulcerative Colitis

Start: 2013-07-31End: 2016-11-30Updated: 2018-08-08

Related Papers

Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis

Clinical Gastroenterology and Hepatology2020-12-038 citations

Randomised non‐inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild‐to‐moderate ulcerative colitis

Alimentary Pharmacology & Therapeutics2017-06-0146 citations

P-102 The Regulatory and Legal Complexity of the Multicentre, Multinational Clinical Trial with TP05

Inflammatory Bowel Diseases2016-02-05